COMMUNIQUÉS West-GlobeNewswire

Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth
05/08/2025
Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-year Second quarter 2025 Total revenues of $478 million, up 34% year-over-year Second quarter 2025 profitability metrics with GAAP Net loss [...]
LifeMD Reports Second Quarter 2025 Results
05/08/2025
Total revenue increased 23% year-over-year to $62.2 million; adjusted EBITDA rose 223% to $7.1 million Telehealth revenue increased 30% to $48.6 million; telehealth adjusted EBITDA rose 560% to $3.4 million Generated [...]
Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study
05/08/2025
PONTE VEDRA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
05/08/2025
Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds 1 of $9.5 million, revenue increased 5% year-over-year. Second quarter 2025 hereditary [...]
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
05/08/2025
Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates expected in 4Q25 Phase 2 trial of TERN-601 for obesity [...]
Ceribell Reports Second Quarter 2025 Financial Results
05/08/2025
SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Amwell® Announces Results for Second Quarter 2025
05/08/2025
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended [...]
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
05/08/2025
Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: In patients with type 2 diabetes (T2D) not achieving glycemic targets, icovamenib [...]
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
05/08/2025
DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025
05/08/2025
CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi [...]
LeMaitre Q2 2025 Financial Results
05/08/2025
BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0. [...]
Supernus Announces Second Quarter 2025 Financial Results
05/08/2025
Net sales of Qelbree ® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, [...]
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update
05/08/2025
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 6 3% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months - Based on the [...]
Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
05/08/2025
JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value [...]
Fractyl Health Announces Proposed Public Offering
05/08/2025
BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company pioneering pattern-breaking approaches that treat root causes of [...]
Galecto Reports Second Quarter 2025 Operating and Financial Results
05/08/2025
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and [...]
BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
05/08/2025
MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based [...]
Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations
06/08/2025
DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations [...]
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
06/08/2025
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]

Pages